000026522 000__ 08282cam\a2200865\i\4500
000026522 001__ 26522
000026522 003__ SzGeWIPO
000026522 005__ 20230703093534.0
000026522 008__ 100419s2011\\\\enk\\\\\rbjl\\001\0\eng\\
000026522 020__ $$a9780199609451$$qv. 1
000026522 020__ $$a9780199289011$$qPrint
000026522 035__ $$a(wipo)006129270
000026522 035__ $$a(OCoLC)728542680
000026522 040__ $$aSzZuIDS NEBIS EPF-BIB$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000026522 041__ $$aeng
000026522 043__ $$au-at---
000026522 050_4 $$aK1517$$b.P48 2011
000026522 050_4 $$aK1401$$b.P53 2010
000026522 08204 $$a346.048$$222
000026522 084__ $$aG 42 BUC.P
000026522 090__ $$c28918$$d28908
000026522 1001_ $$aBucknell, Duncan.$$eEditor.
000026522 24510 $$aPharmaceutical, Biotechnology and Chemical Inventions :$$bWorld Protection and Exploitation.
000026522 264_1 $$aOxford :$$bOxford University Press,$$c2011.
000026522 300__ $$a2 volumes ;$$c25 cm
000026522 336__ $$atext$$btxt$$2rdacontent
000026522 337__ $$aunmediated$$bn$$2rdamedia
000026522 338__ $$avolume$$bnc$$2rdacarrier
000026522 504__ $$aIncludes bibliographical references and index.
000026522 5050_ $$aPart A. Introduction and Overview -- Part B. Fundemental Concepts -- 1. Overview; 2. International treaties; 3. Skilled addressee; 4. Interpretation of patent claims and specifications; 5. Inventorship; 6. Ownership -- Part C. Obtaining patent rights -- 1. Overview; 2. Drafting bioscience patents; 3. Drafting pharmaceutical patents; 4. Overview of procedure from filing to grant; 5. Types of examination and when to use them; 6. Prosecution strategies; 7. Types of application and their use; 8. Disclosure of information to the patent offices -- Part D. The period of the monopoly -- 1. Overview; 2. The patent term, renewal fees, withdrawals, cease & lapse; 3. Extensions of term and supplementary protection certificates -- Part E. Patent validity -- 1. Overview; 2. Patent validity; 3. Priority dates; 4. Novelty; 5. Grace period; 6. Inventive step; 7. Enablement/internal fair basis; 8. Full description/stuffiness/written description; 9. Utility; 10. Indefiniteness; 11. Secret use before prior date; 12. Unity of invention; 13. Fraud and misrepresentation; 14. Lack of entitlement to the invention -- Part F. Amendment -- 1. Overview; 2. When Patents can be added?; 3. What amendments are allowable?; 4. Amended specifications -- Part G. Invalidity proceedings and strategy -- 1. Overview; 2. Third part intervention during prosecution; 3. Opposition proceedings; 4. Re-examination; 5. Revocation/nullification proceedings; 6. Declarations of validity -- Part H. Infringement -- 1. Overview; 2. Literal infringement; 3. Infringement equivalents; 4. Contributory infringement; 5. Infringement proceedings & strategy; 6. Remedies for patent infringements; 7. Restrictions on remedies -- Part I. Defences to infringement -- 1. Overview; 2. Prior secret use; 3. Experimental use and clinical trials; 4. The bolar exemption; 5. Contributory infringement; 6. Parallel importing and exhaustion of rights -- Part J. Patent litigation strategies -- 1. Overview; 2. Court hierarchies; 3. Overview of litigation; 4. Preliminary injunctions; 5. Split trials; 6. Summary judgments; 7. Multi-jurisdictional strategy; 8. Practicalities of litigation; 9. Settlement of litigation -- Part K. Interaction between regulatory approval and patents -- 1. Overview; 2. Regulatory bodies and relevant legislation; 3. The pharmaceutical regulatory approval process; 4. The biologicals regulatory approval process; 5. The medical device regulatory approval process; 6. The agricultural chemicals regulatory approval process; 7. Regulatory filing strategies adopted by innovator companies; 8. Regulatory filing strategies adopted by generic companies; 9. Other relevant regulatory laws -- Part L. Data exclusivity -- 1. Overview; 2. Comparison of data exclusivity with other right; 3. New chemical entity data exclusivity periods for pharmaceuticals; 4. Other data exclusivity periods for pharmaceuticals; 5. Certified (listed) patents and approval of generic drugs; 6. Data exclusivity strategies adopted by innovator companies; 7. Data exclusivity strategies adopted by generic companies; 8. Medical devices, agricultural chemicals and other non-pharmaceuticals -- Part M. Competition law -- 1. Overview; 2. Legal basis for IP as an exception to competition (anti-trust) law; 3. Technology transfer arrangements (including Block Exemption); 4. Tie-in clauses / Tie-out clauses; 5. Licenses which extend beyond patent term; 6. Disclosure to industry standard setting organizations; 7. Unjustified threats of patent infringement proceedings; 8. Competition issues in settlement of litigation -- Part N. Other IP rights -- 1. Overview; 2. Competition issues in settlement of litigation; 3. Plant breeder's rights; 4. Trade marks, passing off and unfair competition -- Part O. Commercial arrangements -- 1. Oveview; 2. Research & development collaboration; 3. Commercialisation strategies; 4. Licensing; 5. Assignments; 6. IP due diligence; 7. Compulsory licenses; 8. Compulsory use or acquisition by government -- Tables and Figures
000026522 520__ $$aThis book highlights the special issues arising in obtaining, commercialising, enforcing or attacking intellectual property rights (including protection of regulatory data) in the pharmaceutical, biotechnology and chemical industries across the world's key jurisdictions. It is unique in presenting topic matter horizontally by subject to facilitate comparison between country practices. The first two chapters give a general introduction to the differences between the jurisdictions and an overview of some of the key concepts in patent law. The remainder of the book is dedicated to a detailed analysis of the major legal issues arising in these areas of technology. Each component chapter has a comparative introduction, looking at the variances in the laws of different domains, followed by side-by-side analysis of the relevant regimes, including tables and flow-charts which summarise and explain the key legal concepts. The jurisdictions covered are the United States, Europe (UK, Germany, Netherlands, France and Italy), Japan, Canada, Australia, India and China.
000026522 650_0 $$aPatent laws and legislation$$zUnited States.
000026522 650_0 $$aIntellectual property$$zUnited States.
000026522 650_0 $$aIndustrial property$$zUnited States.
000026522 650_0 $$aPharmacy$$xLaw and legislation.
000026522 650_0 $$aBiotechnology industries$$xLaw and legislation.
000026522 650_0 $$aDrugs$$zUnited States.
000026522 650_0 $$aChemical industry$$xLaw and legislation.
000026522 650_0 $$aChemicals$$xPatents.
000026522 650_0 $$aPharmaceutical biotechnology$$xLaw and legislation.
000026522 650_0 $$aPatent laws and legislation.
000026522 650_0 $$aIntellectual property.
000026522 650_0 $$aIndustrial property.
000026522 650_0 $$aPharmaceutical industry$$xLaw and legislation.
000026522 650_0 $$aPatent infringement$$zEurope.
000026522 650_4 $$aPatents
000026522 650_4 $$aBiotechnology
000026522 651_0 $$aEurope$$xCommerce$$xLaw and legislation.
000026522 651_0 $$aUnited Kingdom$$xCommerce$$xLaw and legislation.
000026522 651_0 $$aFrance$$xCommerce$$xLaw and legislation.
000026522 651_0 $$aIndia$$xCommerce$$xLaw and legislation.
000026522 651_0 $$aChina$$xCommerce$$xLaw and legislation.
000026522 651_0 $$aItaly$$xCommerce$$xLaw and legislation.
000026522 651_0 $$aAustralia$$xCommerce$$xLaw and legislation.
000026522 651_0 $$aJapan$$xCommerce$$xLaw and legislation.
000026522 651_0 $$aGermany$$xCommerce$$xLaw and legislation.
000026522 651_0 $$aCanada$$xCommerce$$xLaw and legislation.
000026522 651_0 $$aUnited States$$xCommerce$$xLaw and legislation.
000026522 655_7 $$aPatents.$$2lcgft
000026522 655_7 $$aLegislative materials.$$2lcgft
000026522 7001_ $$aPravin Anand,$$aJohn Bateman,$$aSusan Beaubien,$$aTheo Bodewig,$$aSimon Cohen,$$aWayne Condon,$$aMarina Couste,$$aRobert A. Dormer,$$aAtsushi Hakoda,$$aJuany Huang,$$aReuben E. Jacob,$$aFabrizio Jacobacci,$$aKurt R. Karst,$$aKlaus Kupka,$$aDavid C. Musker,$$aCyra Nargolwalla,$$aNina Resinek,$$aToshio Takizawa,$$aKoichi Tsujii,$$aKlaus Schweitzer,$$aDeborah Somerville,$$aPaul Steinhauser,$$aNigel Stoate,$$aRosie Stramandinoli,$$aOtto Swens,$$aAndreas Walkenhorst,$$aSilvie Wertwijn,$$aWilliam Yang,$$aFederico Zanardi Landi.$$eContributors.
000026522 8524_ $$bE02$$cE02HA$$j347.771 BUC$$pEM000007112978
000026522 8524_ $$bE02$$cE02HA$$j347.771 BUC$$pEM000007112979
000026522 942__ $$cMON$$jG 42 BUC.P
000026522 952__ $$w2011-07-29$$p2011-0413$$r280.25$$u40952$$bMAIN$$10$$kG 42 BUC.P (I)$$v2011-07-29$$zTagged$$71
000026522 952__ $$w2011-07-29$$p2011-0414$$r280.25$$u40953$$bMAIN$$10$$kG 42 BUC.P (II)$$v2011-07-29$$zTagged$$71
000026522 952__ $$w2011-09-12$$p2011-0444$$r0.00$$u40983$$bMAIN$$10$$kG 42 BUC.P (I)$$v2011-09-12$$zTagged$$71
000026522 952__ $$w2011-09-12$$p2011-0445$$r0.00$$u40984$$bMAIN$$10$$kG 42 BUC.P (II)$$v2011-09-12$$zTagged$$71
000026522 980__ $$aBIB
000026522 999__ $$c28918$$d28918